Research programme: deubiquitinating enzyme inhibitors - Almac Discovery
Latest Information Update: 21 Jan 2021
At a glance
- Originator Almac Discovery
- Class Antineoplastics; Small molecules
- Mechanism of Action Deubiquitinating enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Colorectal cancer